OPPENHEIMER’S 24TH ANNUAL HEALTHCARE CONFERENCE PROVIDES INVESTOR ACCESS TO EMERGING AND ESTABLISHED COMPANIES

New York, December 13, 2013 – Oppenheimer & Co. Inc., a unit of Oppenheimer Holdings Inc., is pleased to announce the completion of its 24th Annual Healthcare Conference, which took place on December 10 – 11, 2013, in New York. More than 130 public and private companies, representing all major sectors of the healthcare industry including bio & specialty pharmaceuticals; biotechnology; medical devices; healthcare facilities; life science tools and diagnostics; healthcare information technology and distribution, and healthcare providers and servicers participated in this two-day program. The conference attracted more than 700 attendees.

The Oppenheimer Healthcare Conference consisted of a mix of formal company presentations and one-on-one meetings.

The keynote speaker Ted Kennedy, Jr., President & Co-Founder, The Marwood Group, provided insights into the latest developments in Washington, D.C. and discussed the regulatory environment as well as the headwinds and tailwinds across many sectors of the healthcare industry.

“This is Oppenheimer’s 24th consecutive year of producing this conference, and it demonstrates our long-standing commitment to the healthcare industry. We are pleased to be able to continue to offer this conference for investors to meet with emerging and established healthcare companies as they evaluate the opportunities in the sector over the next 12-18 months,” said Erica Moffett, Managing Director and Associate Director of Research.

Panels included “How Emerging Biopharma Companies Successfully Execute Their First Commercial Launch,” and “China Healthcare Holds Opportunities for Global Investors and Healthcare Companies:
How to Capture Them?” Other panels looked at the growing use of big data in healthcare and the evolving healthcare model which included CEOs of two of the leading hospital systems in the U.S. discussing the significant payment and care delivery changes ahead.

In the current environment of healthcare reform, increased regulation and rising costs, the conference offered investors a unique opportunity to meet with CEOs and CFOs of healthcare companies and learn first hand what issues and trends will drive the sector in 2014 and beyond in the U.S., Europe and China.

“The Oppenheimer Healthcare Conference has been an excellent forum to highlight our plans for launching OTREXUP following the NDA approval in October,” said Paul Wotton, President and CEO of Antares Pharma.

Oppenheimer provides research coverage of more than 110 companies in the healthcare sector and is an active underwriter of healthcare stocks.

Oppenheimer & Co. Inc., a principal subsidiary of Oppenheimer Holdings Inc. (OPY on the New York Stock Exchange), provides a full range of wealth management, securities brokerage and investment banking services to high-net-worth individuals, families, corporate executives, local governments, businesses and institutions.

Certain statements in this release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, as discussed in the Company’s filings with the Securities and Exchange Commission.

-o-

FOR FURTHER INFORMATION
Stefan Prelog, (212) 931-6139